YM-53601 (Standard)
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


YM-53601 (Standard)
Description:
YM-53601 (Standard) is the analytical standard of YM-53601 (HY-100313A) . This product is intended for research and analytical applications. YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo[1]. YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent[2]. YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation[3].Target:
Farnesyl Transferase; HCV; Reference StandardsRelated Pathways:
Anti-infection; Metabolic Enzyme/Protease; OthersField of Research:
Infection; Metabolic DiseaseSmiles:
F/C(COC1=CC(NC2=C3C=CC=C2)=C3C=C1)=C4CN5CCC/4CC5.[H]ClMolecular Formula:
C21H22ClFN2OMolecular Weight:
372.86References & Citations:
[1]T Ugawa, et al. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br J Pharmacol. 2000 Sep;131 (1) :63-70. |[2]Tsukasa Ishihara, et al. Syntheses of 3-ethylidenequinuclidine derivatives as squalene synthase inhibitors. Part 2: enzyme inhibition and effects on plasma lipid levels. Bioorg Med Chem. 2003 Aug 15;11 (17) :3735-45. |[3]Eun-Mee Park, et al. Farnesyl-diphosphate farnesyltransferase 1 regulates hepatitis C virus propagation. FEBS Lett. 2014 May 2;588 (9) :1813-20. |[4]Joan Montero, et al.Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res. 2008 Jul 1;68 (13) :5246-56.Shipping Conditions:
Room temperatureScientific Category:
Reference StandardsCAS Number:
[182959-33-7]
